Serina Therapeutics, Inc. (SER) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study, titled “A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients With Parkinson’s Disease and Motor Fluctuations,” aims to test a new drug device combo for better movement control in advanced Parkinson’s disease. It focuses on safety and how the drug moves through the body, a key early step before larger trials.
The main treatment is SER-252, a drug based on apomorphine given under the skin, paired with the wearable enFuse device. It is designed to give controlled dosing that could smooth out motor ups and downs and offer a more convenient option than traditional injections or infusions.
This is an interventional Phase 1 trial where patients are randomly placed into different groups that either get SER-252 or a placebo. Both patients and doctors are blinded to who receives what, and the core goal is to check safety and early treatment signals rather than prove full effectiveness.
The trial was first submitted on Feb. 5, 2026, marking its formal launch into the clinical system. The latest update on Mar. 2, 2026, confirms that the study remains in the recruiting stage, which signals progress but also that no outcome data is yet available.
For investors, this update reinforces that Serina Therapeutics is moving its Parkinson’s pipeline into human testing, a key milestone that can support longer term value if early safety is clean. In a space with major incumbents and active device players, even a modestly positive early readout could lift sentiment on SER, though near term volatility is likely as the company remains in a high-risk, early clinical phase.
The study is currently ongoing with recruiting status, and more details and future updates are available on the ClinicalTrials portal.
To learn more about SER’s potential, visit the Serina Therapeutics, Inc. drug pipeline page.